Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
UNIVERSITY OF ZURICH holds a patent portfolio in the Biotechnology & Pharmaceuticals technology area with 1 pending office action. This action is assigned to 1 distinct examiner, SHIAO, REI TSANG. The prosecution is currently active in 1 distinct art unit, indicating a specific technical focus for the pending Biotechnology & Pharmaceuticals work.
SHIAO, REI TSANG is the busiest examiner for the portfolio, managing 1 pending office action. Since there is only 1 distinct examiner, the entire pending workload is centralized. This allows for a direct prosecution path within the 1 distinct art unit involved in the current review process.
Practitioners should note that the 1 pending office action represents the university's current active matter at the patent office. With 1 distinct examiner handling the case, the prosecution strategy is focused on a single point of contact. The presence of 1 distinct art unit further emphasizes the targeted nature of the university's current Biotechnology & Pharmaceuticals filings.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHIAO, REI TSANG | 1 | 79.8% | -33.6% |
| TAYLOR, LIA ELAN | 1 | 64.4% | +29.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18506287 | N6-ADENOSINE-METHYLTRANSFERASE INHIBITORS IN CANCER TREATMENT | SHIAO, REI TSANG | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18256817 | HDAC6 BINDING PROTEINS AND THEIR ANTI-VIRAL USE | TAYLOR, LIA ELAN | 55d |
| Art Unit | Apps |
|---|---|
| 1691 | 1 |
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18506287 | N6-ADENOSINE-METHYLTRANSFERASE INHIBITORS IN CANCER TREATMENT | SHIAO, REI TSANG | 1691 | §102§103 | Non-Final OA | — | Pending | Nov 10, 2023 |
| 18256817 | HDAC6 BINDING PROTEINS AND THEIR ANTI-VIRAL USE | TAYLOR, LIA ELAN | 1641 | §112 | Final Rejection | 55d | Pending | Jun 09, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial